The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Diagnosis of HS for at least 6 months prior to screening visit.
A total AN count of at least 4, with no draining tunnels AND
Affecting at least 2 distinct anatomical areas
Agreement to NOT use topical and systemic antibiotics for treatment of HS during the vehicle-controlled period.
Body surface areas to be treated exceed 20% BSA at screening or baseline
Presence of draining tunnels at screening or baseline.
Medical history including current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.
Laboratory values outside of the protocol-defined criteria.